netFormulary NHS
Pan Mersey
Area Prescribing Committee
 Formulary Chapter 6: Endocrine system - Full Section

Coronavirus guidance

Guidance to support primary care prescribers and pharmacists is available from the MLCSU Coronavirus guidance resource page. Links are provided to national resources and regional documents produced by MLCSU, RDTC, and SPS for use by Pan Mersey APC, LSCMMG, and GMMMG.

The list of resources will be updated as new material becomes available so please check back regularly for updates.

The Pan Mersey APC supports the use of COVID-specific guidance issued by NICE, and NHS England and NHS Improvement. During the COVID pandemic this will supersede any APC advice.

Endocrine system

Review date: January 2023

Non-formulary drugs: Any drug or formulation not listed in the formulary is deemed to be non-formulary.

Off-label use: Drugs are included in the formulary for their licensed indications – where inclusion of off-label use is considered to be included in the formulary this is specifically stated in the formulary entry for the drug N.B. also see Paediatrics note below.

Paediatrics: Drugs are included in the formulary for paediatric use for their BNF for Children recommended indications (indicated by symbol View childrens BNF) which may be off-label, unless otherwise stated. All drugs are deemed to have the same RAG status as they have for adults unless stated otherwise.

NHS England Specialised Commissioning
Drugs carrying the NHS England logo are commissioned by them. Links to key documents, national programmes of care, and clinical reference groups are found below.

NHSE NHS England Specialised Commissioning: Key documents

NHSE NHS England Specialised Commissioning: National programmes of care and clinical reference groups

Medications which are indicated for medically assisted reproduction, including ovulation induction (e.g. clomifene, letrozole and tamoxifen) and assisted reproduction, such as In Vitro Fertilisation or Ex Vitro Fertilisation (e.g. gonadotrophins) are restricted to use by specialist secondary care physicians, and are categorised as RED drugs for these purposes.

06.01 Drugs used in diabetes
06.01.01 Insulins Short-acting insulins Intermediate- and long-acting insulins Hypodermic equipment
06.01.02 Antidiabetic drugs Sulphonyureas Biguanides Other antidiabetic drugs
06.01.03 Diabetic ketoacidosis
06.01.04 Treatment of hypoglycaemia
Chronic hypoglycaemia
06.01.05 Treatment of diabetic nephropathy and neuropathy
Diabetic nephropathy
Diabetic neuropathy
06.01.06 Diagnostic and monitoring agents for diabetes mellitus
Blood glucose monitoring
Oral glucose tolerance test
06.02 Thyroid and Antithyroid drugs
06.02.01 Thyroid hormones
06.02.02 Antithyroid drugs
06.03 Corticosteroids
06.03.01 Replacement therapy
06.03.02 Glucocorticoid therapy
06.04 Sex hormones
06.04.01 Female sex hormones and their modulators Oestrogens and HRT
Hormone replacement therapy
Raloxifene Progestogens and progesterone receptor modulators
06.04.02 Male sex hormones and antagonists
Dutasteride and finasteride
06.04.03 Anabolic steroids
06.05 Hypothalamic and pituitary hormones and anti-oestrogens
06.05.01 Hypothalamic and anterior pituitary hormones and anti-oestrogens
Anterior pituitary hormones
Growth Hormone
Growth hormone receptor antagonists
Hypothalmic hormones
06.05.02 Posterior pituitary hormones and antagonists
Posterior pituitary hormones
Antidiuretic hormone antagonists
06.06 Drugs affecting bone metabolism
06.06.01 Calcitonin and parathyroid hormone
06.06.02 Bisphosphonates and other drugs affecting bone metabolism
Strontium renelate
06.07 Other endocrine drugs
06.07.01 Bromocriptine and other dopaminergic drugs
06.07.02 Drugs affecting gonadotrophins
Gonadorelin analogues
Breast pain (mastalgia)
06.07.03 Metyrapone
06.07.04 Somatomedins